15,285 Shares in GSK plc (NYSE:GSK) Acquired by Nwam LLC

Nwam LLC acquired a new stake in GSK plc (NYSE:GSK) in the 3rd quarter, Holdings Channel reports. The institutional investor acquired 15,285 shares of the pharmaceutical company’s stock, valued at approximately $625,000.

Other institutional investors have also recently made changes to their positions in the company. Natixis Advisors LLC increased its holdings in GSK by 20.0% during the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock valued at $20,460,000 after purchasing an additional 83,433 shares during the period. Van ECK Associates Corp raised its holdings in shares of GSK by 8.4% during the third quarter. Van ECK Associates Corp now owns 736,510 shares of the pharmaceutical company’s stock valued at $27,973,000 after acquiring an additional 56,843 shares in the last quarter. Cohen Investment Advisors LLC purchased a new stake in GSK in the second quarter worth $349,000. Equity Investment Corp boosted its holdings in GSK by 1.8% in the third quarter. Equity Investment Corp now owns 3,496,254 shares of the pharmaceutical company’s stock valued at $142,927,000 after acquiring an additional 63,052 shares in the last quarter. Finally, Stockman Wealth Management Inc. increased its position in GSK by 7.7% during the 3rd quarter. Stockman Wealth Management Inc. now owns 209,517 shares of the pharmaceutical company’s stock valued at $8,565,000 after purchasing an additional 15,024 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and dropped their target price for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Argus raised GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Barclays raised GSK to a “hold” rating in a research report on Tuesday, August 27th. Seven equities research analysts have rated the stock with a hold rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $43.25.

Insider Activity

In other news, major shareholder Plc Gsk purchased 2,791,930 shares of GSK stock in a transaction that occurred on Friday, September 27th. The stock was bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the transaction, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. The trade was a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

GSK Stock Up 0.8 %

GSK stock opened at $33.96 on Friday. The business has a 50 day moving average of $38.09 and a 200 day moving average of $40.35. The firm has a market cap of $70.38 billion, a PE ratio of 22.05, a price-to-earnings-growth ratio of 1.29 and a beta of 0.66. GSK plc has a twelve month low of $32.83 and a twelve month high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be paid a $0.3928 dividend. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.63%. The ex-dividend date is Friday, November 15th. GSK’s dividend payout ratio is currently 99.35%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.